DEPO - Depomed, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.32
-0.29 (-3.81%)
At close: 4:00PM EDT

7.32 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close7.61
Open7.61
Bid7.29 x 3200
Ask7.75 x 2900
Day's Range7.31 - 7.70
52 Week Range4.31 - 11.27
Volume630,225
Avg. Volume1,315,100
Market Cap465.46M
Beta0.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of DEPO earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Depomed Inc Earnings Call

  • Why Depomed Inc.'s Shares Soared 23.2% Higher
    Motley Fool11 days ago

    Why Depomed Inc.'s Shares Soared 23.2% Higher

    The company rewarded investors with good news today.

  • Associated Press12 days ago

    Depomed: 1Q Earnings Snapshot

    The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $499 million.

  • Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?
    Simply Wall St.last month

    Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?

    Analyzing Depomed Inc’s (NASDAQ:DEPO) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?
    Simply Wall St.2 months ago

    When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?

    Depomed Inc’s (NASDAQ:DEPO): Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States.Read More...

  • CNBC2 months ago

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?
    Simply Wall St.2 months ago

    Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?

    Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. Depomed’s insiders haveRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $131 million.

  • This Biotech Flirts With Breakout Amid Battle With Opioid Makers
    Investor's Business Daily2 months ago

    This Biotech Flirts With Breakout Amid Battle With Opioid Makers

    Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.

  • Exploring Depomed’s Financial Performance Today
    Market Realist2 months ago

    Exploring Depomed’s Financial Performance Today

    In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.

  • Inside Depomed’s Portfolio: The Key Drugs
    Market Realist2 months ago

    Inside Depomed’s Portfolio: The Key Drugs

    Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.

  • Behind Depomed’s Business Strategy
    Market Realist2 months ago

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist2 months ago

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of DEPO earnings conference call or presentation 27-Feb-18 9:30pm GMT

    Q4 2017 Depomed Inc Earnings Call

  • Here's Why Depomed Inc Fell as Much as 13.8% Today
    Motley Fool3 months ago

    Here's Why Depomed Inc Fell as Much as 13.8% Today

    The company announced full-year 2017 earnings yesterday after the market closed.

  • Associated Press3 months ago

    Depomed reports 4Q loss

    On a per-share basis, the Newark, California-based company said it had a loss of 52 cents. Earnings, adjusted for non-recurring costs and pretax expenses, were 15 cents per share. The results beat Wall ...

  • Benzinga3 months ago

    The Week Ahead In Biotech: Earnings, PDUFA Dates And More

    The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $384 million.

  • Benzinga3 months ago

    The Week Ahead In Biotech: Earnings, PDUFA Dates And More

    Volatility is the name of the game in profitable trading, and it's all the more relavant in the biotech space, which is subject to many make-or-break catalytic events . This apart, usual market-moving ...

  • Should You Buy Depomed Inc (NASDAQ:DEPO)?
    Simply Wall St.3 months ago

    Should You Buy Depomed Inc (NASDAQ:DEPO)?

    Depomed Inc (NASDAQ:DEPO), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $8.67Read More...

  • TheStreet.com3 months ago

    Opioid Litigants Get Boost From Senate Report

    A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

  • Reuters3 months ago

    Opioid makers paid millions to advocacy groups -U.S. Senate report

    Five opioid manufacturers including OxyContin maker Purdue Pharma LP have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday. The report, released by Democratic Senator Claire McCaskill, said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42,000 opioid overdose deaths. The report released by McCaskill, the U.S. Senate Homeland Security and Governmental Affairs Committee's ranking Democrat, said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use.